Clinical Trial Results - Cancer Currents Blog
Reports on findings from cancer clinical trials, with commentary from leading researchers on how the trial results will affect patient care.
-
The investigational drug selpercatinib may benefit patients with lung cancer whose tumors have alterations in the RET gene, including fusions with other genes, according to results from a small clinical trial.
-
For many children with high-risk neuroblastoma, receiving two separate stem cell transplants is more beneficial than receiving one, according to the results of an NCI-supported clinical trial conducted by the Children’s Oncology Group.
-
Researchers tested a program that trains pediatricians’ offices to provide smoking cessation treatment to parents during visits with their child’s doctor. The approach is intended to reach adults who are motivated to quit to protect their child’s health.
-
An NCI-funded clinical trial is testing the immunotherapy drug nivolumab (Opdivo) in people who have advanced cancer and an autoimmune disease, such as rheumatoid arthritis, lupus, or multiple sclerosis, who are often excluded from such trials.
-
New clinical trial findings confirm that the targeted therapy erdafitinib (Balversa) can benefit patients with advanced bladder cancer whose tumors have a genetic alteration in one of the four FGFR genes.
-
Some women with endometrial cancer may be able to receive less intensive treatment, chemotherapy and no radiation, without increasing their risk of the disease recurring within 5 years, according to the results of a randomized clinical trial.
-
Olaparib (Lynparza) may be beneficial for some people with advanced pancreatic cancer who have inherited mutations in the BRCA1 or BRCA2 genes, according to results from the POLO trial.
-
In two large clinical trials, the drugs enzalutamide (Xtandi) and apalutamide (Erleada), respectively, combined with the androgen deprivation therapy, improved the survival of men with metastatic prostate cancer that still responds to hormone-suppressing therapies.
-
The drug lenalidomide (Revlimid) may delay the progression of smoldering myeloma to multiple myeloma, according to preliminary results from a clinical trial.
-
New findings from a clinical trial suggest that a single dose of radiation therapy may control painful bone metastases as effectively as multiple lower doses of radiation therapy.